A detailed history of Dimensional Fund Advisors LP transactions in Insmed Inc stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 367,252 shares of INSM stock, worth $24.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
367,252
Previous 12,089 2937.9%
Holding current value
$24.3 Million
Previous $809,000 3213.84%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$62.0 - $79.01 $22 Million - $28.1 Million
355,163 Added 2937.9%
367,252 $26.8 Million
Q2 2024

Aug 09, 2024

BUY
$22.0 - $69.71 $265,958 - $842,724
12,089 New
12,089 $809,000
Q4 2023

Feb 07, 2024

BUY
$23.42 - $31.74 $22,342 - $30,279
954 Added 1.32%
73,073 $2.26 Million
Q3 2023

Nov 09, 2023

BUY
$19.86 - $26.93 $20,992 - $28,465
1,057 Added 1.49%
72,119 $1.82 Million
Q2 2023

Aug 09, 2023

SELL
$16.44 - $21.1 $13,332 - $17,112
-811 Reduced 1.13%
71,062 $1.5 Million
Q1 2023

May 12, 2023

SELL
$16.26 - $21.73 $118,177 - $157,933
-7,268 Reduced 9.18%
71,873 $1.23 Million
Q4 2022

Feb 09, 2023

SELL
$16.98 - $23.15 $530,981 - $723,923
-31,271 Reduced 28.32%
79,141 $1.58 Million
Q3 2022

Nov 10, 2022

SELL
$20.88 - $28.21 $1.56 Million - $2.11 Million
-74,639 Reduced 40.33%
110,412 $2.38 Million
Q2 2022

Aug 12, 2022

SELL
$17.07 - $25.71 $7.5 Million - $11.3 Million
-439,258 Reduced 70.36%
185,051 $3.65 Million
Q1 2022

May 13, 2022

BUY
$20.42 - $28.13 $4.39 Million - $6.05 Million
215,093 Added 52.56%
624,309 $14.7 Million
Q4 2021

Feb 09, 2022

BUY
$25.89 - $33.45 $7.61 Million - $9.83 Million
293,890 Added 254.83%
409,216 $11.1 Million
Q3 2021

Nov 12, 2021

BUY
$22.46 - $29.47 $2.59 Million - $3.4 Million
115,326 New
115,326 $3.18 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.98B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.